Matches in Wikidata for { <http://www.wikidata.org/entity/Q92192633> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q92192633 description "clinical trial" @default.
- Q92192633 description "ensayo clínico" @default.
- Q92192633 description "ensayu clínicu" @default.
- Q92192633 description "klinisch onderzoek" @default.
- Q92192633 description "клінічне випробування" @default.
- Q92192633 name "Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients" @default.
- Q92192633 name "Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients" @default.
- Q92192633 type Item @default.
- Q92192633 label "Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients" @default.
- Q92192633 label "Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients" @default.
- Q92192633 prefLabel "Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients" @default.
- Q92192633 prefLabel "Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients" @default.
- Q92192633 P1050 Q92192633-16C2EF7A-4851-4B4C-B56A-96E8E7ADB5D5 @default.
- Q92192633 P1132 Q92192633-8E61A997-C733-4B73-8489-2DCAE063AF03 @default.
- Q92192633 P1476 Q92192633-E3841ABD-BAD6-4701-8FA7-03041B84E32C @default.
- Q92192633 P17 Q92192633-CFA982CF-5E6A-416F-A02F-70D758F09782 @default.
- Q92192633 P1813 Q92192633-9E976BAE-BC88-44C8-BC4A-9FAF7B5FFD94 @default.
- Q92192633 P2899 Q92192633-B0342A88-DD34-4307-8D6A-74465B5A3DF6 @default.
- Q92192633 P3098 Q92192633-79F86443-FA1A-4EDC-B386-3DBA7FD5F0FB @default.
- Q92192633 P31 Q92192633-4A7AB868-05A6-4237-A651-7A6EBE3E1921 @default.
- Q92192633 P4844 Q92192633-3668C999-82B3-453B-9517-BEF853A28C5B @default.
- Q92192633 P4844 Q92192633-C9D103E5-8C1E-4A3E-8139-421F7C907766 @default.
- Q92192633 P580 Q92192633-4DECADB2-C318-4E9F-8252-3F1C46F04F0A @default.
- Q92192633 P582 Q92192633-0FB8C2D9-326B-4940-8891-9F58FC2BAFFB @default.
- Q92192633 P6099 Q92192633-E60A77E1-C927-425F-88B4-F31E603063CD @default.
- Q92192633 P767 Q92192633-95DD0F42-5B74-46FE-8537-612141F0216D @default.
- Q92192633 P8363 Q92192633-1BCBC5E0-B073-4717-8078-D5F8E2D9F758 @default.
- Q92192633 P1050 Q356033 @default.
- Q92192633 P1132 "+307" @default.
- Q92192633 P1476 "MAZEPPA: Phase II PRODIGE-GERCOR Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients" @default.
- Q92192633 P17 Q142 @default.
- Q92192633 P1813 "D19-02" @default.
- Q92192633 P2899 "+18" @default.
- Q92192633 P3098 "NCT04348045" @default.
- Q92192633 P31 Q30612 @default.
- Q92192633 P4844 Q19904005 @default.
- Q92192633 P4844 Q7083106 @default.
- Q92192633 P580 "2020-05-01T00:00:00Z" @default.
- Q92192633 P582 "2022-12-01T00:00:00Z" @default.
- Q92192633 P6099 Q42824440 @default.
- Q92192633 P767 Q731938 @default.
- Q92192633 P8363 Q78089383 @default.